González-Pinto A, López Ibor J J, Sáiz J, Gutiérrez M, Figuerido J L, García Godoy M J
Hospital Santiago Apóstol, Vitoria.
Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1996 Nov-Dec;24(6):303-9.
Neuroendocrine challenge paradigms have been used to assess serotonergic system in depression but limitations in the specificity of many of these tests have been noted. In this study, the neuroendocrine responses to acute intravenous administration of the serotonin (5-HT) reuptake inhibitor clomipramine were assessed in patients with Major Depression with Melancholia (DMM) and matched subjects with Major Depression (DM) (without Melancholia) and Dysthimic disorder (TD).
10 patients who met DSM III-R criteria of DMM, 10 patients with DM and 10 with DD matched for age and sex received 12.5 mg of intravenously administered clomipramine. Prl, Cortisol and GH were measured during the next 135 minutes.
The DMM patients had significant blunting prolactin responses to clomipramine compared with the other patients.
These data support the hypothesis that DMM patients have abnormal neuroendocrine responses to the intravenous administration of the 5-HT reuptake inhibitor clomipramine and that they are different from the DM and TD patients.
神经内分泌激发范式已被用于评估抑郁症中的血清素能系统，但已注意到其中许多测试在特异性方面存在局限性。在本研究中，对伴有忧郁症的重度抑郁症（DMM）患者、匹配的重度抑郁症（DM）（无忧郁症）患者和心境恶劣障碍（TD）患者进行了血清素（5-HT）再摄取抑制剂氯米帕明急性静脉给药后的神经内分泌反应评估。
10名符合DMM的DSM III-R标准的患者、10名DM患者和10名年龄和性别匹配的DD患者接受了12.5毫克静脉注射氯米帕明。在接下来的135分钟内测量催乳素（Prl）、皮质醇和生长激素（GH）。
与其他患者相比，DMM患者对氯米帕明的催乳素反应明显减弱。
这些数据支持以下假设，即DMM患者对静脉注射5-HT再摄取抑制剂氯米帕明有异常的神经内分泌反应，且与DM和TD患者不同。
